

IN THE CLAIMS:

Please cancel claims 1 to 30 without prejudice. Please add new claims 31 to 53 as follows:

1.-30. (Cancel)

31. (New) An antibody or a functional fragment thereof having amino acid sequences of a heavy chain variable region and a light chain variable region of the antibody produced by a hybridoma 4D11 (Accession No: FERM BP-7758).

32. (New) An antibody or a functional fragment thereof having amino acid sequences of the mature portions of a heavy chain variable region and a light chain variable region of the antibody produced by a hybridoma 4D11, which are respectively represented by SEQ ID NO:48 and SEQ ID NO:50.

33. (New) An antibody or a functional fragment thereof having amino acid sequences of the mature portions of a heavy chain variable region and a light chain variable region of the antibody, which are represented by SEQ ID NO:48 and SEQ ID NO:50, respectively.

34. (New) An antibody or a functional fragment thereof having amino acid sequences, which respectively range from the 27th Q residue to the 147th S residue of SEQ ID NO:48 and the 23rd A residue to the 128th K residue of SEQ ID NO:50.

35. (New) An antibody or a functional fragment thereof which recognizes an epitope of human CD40 that the antibody or a functional fragment thereof produced by a hybridoma 4D11 (Accession No: FERM BP-7758) recognizes.

36. (New) The antibody or the functional fragment thereof of any one of claims 31 to 35, which is a human antibody.

37. (New) A pharmaceutical composition, containing as an active ingredient the antibody or the functional fragment thereof of any one of claims 31 to 36.

38. (New) The pharmaceutical composition of claim 37, wherein the antibody or the functional fragment is in an effective dose for immunosuppression, anti-autoimmune disease treatment, treatment of allergies or treatment of blood coagulation factor VIII-inhibiting syndrome.

39. (New) A hybridoma 4D11 (Accession No: FERM BP-7758).

40. (New) An antibody or a functional fragment thereof produced by a hybridoma 4D11 (Accession No: FERM BP-7758).
41. (New) A nucleic acid encoding a heavy chain variable region of an antibody isolated from a hybridoma 4D11 (Accession No: FERM BP-7758).
42. (New) The nucleic acid of claim 41, which is RNA or cDNA.
43. (New) A nucleic acid encoding a light chain variable region of an antibody isolated from a hybridoma 4D11 (Accession No: FERM BP-7758).
44. (New) The nucleic acid of claim 43, which is RNA or cDNA.
45. (New) A vector containing the nucleic acid of claims 41 or 43.
46. (New) A host cell containing the vector of claim 45.
47. (New) A method of producing an antibody or a functional fragment thereof, comprising culturing the host cell of claim 46 under conditions allowing expression of heavy or light chain variable regions thereby producing the anti-CD40 antibody or functional fragment.
48. (New) An antibody or a functional fragment thereof having amino acid sequences of the mature portions of a heavy chain variable region and a light chain variable region that are encoded by nucleic acid sequences isolated from a hybridoma 4D11, which are respectively represented by SEQ ID NO:47 and SEQ ID NO:49.
49. (New) An antibody or a functional fragment thereof, having amino acid sequences encoded by nucleic acid sequences which respectively range from the 94th C to the 456th A of SEQ ID NO:47 and from the 125th G to the 442nd A of SEQ ID NO:49.
50. (New) A method of producing an anti-CD40 antibody or a functional fragment thereof, comprising culturing a host cell containing nucleic acid that encodes a heavy chain variable region or a light chain variable region of the antibody isolated from a hybridoma 4D11 (Accession No: FERM BP-7758) under conditions allowing expression of heavy or light chain variable region thereby producing the anti-CD40 antibody or functional fragment thereof.
51. (New) The functional fragment according to claim 31, wherein the fragment comprises a heavy chain variable region or a light chain variable region of the antibody produced by a hybridoma 4D11.
52. (New) The functional fragment according to claim 32, wherein the fragment comprises a mature portion of a heavy chain variable region or a mature portion of a light chain variable

region of the antibody, which are respectively represented by SEQ ID NO:48 and SEQ ID NO:50.

53. (New) A method of treating immunological rejection or GVDH upon organ transplantation, autoimmune disease, an allergy or blood coagulation factor VIII-inhibiting syndrome, comprising administering the antibody or the functional fragment thereof of any of claims 31 to 35, 40, 48 and 49 to a patient.